Date: March 23, 2020  
To: Calgary Zone NICU Physicians, Nursing Staff, and Unit Managers  
From: Dr. Davinder Sidhu, Section Chief, Transfusion Medicine, South Sector, Alberta Precision Laboratories (APL)  
Re: Discontinuation of Maternal Immune Anti-A/B Testing

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

• Effective March 26, 2020, Transfusion Medicine will discontinue Maternal Immune Anti-A or Anti-B testing to confirm the reason for a positive DAT on a neonate.  
• A chartable comment will now be appended to the positive DAT result stating “Positive DAT consistent with ABO HDN”.

Why this is Important:

• Physicians will no longer see discrete results for the Maternal Immune Anti-A or B on the patients chart.  
• There may be other reasons the DAT is positive and should not be ruled out based on comment. Further testing may be performed at physician’s request. Please contact Transfusion Medicine at 403-944-1367.

Background:

• This change is being implemented in an effort to standardize Maternal Immune Anti-A/B testing across the province and laboratory management of positive neonatal DATs.

Inquiries and feedback may be directed to:

• Janice Gosling, Regional Technologist III, 403-956-1425, Janice.Gosling@albertaprecisionlabs.ca  
• Joanna McCarthy, Regional Technologist III, 403-944-8466, Joanna.McCarthy@albertaprecisionlabs.ca

This bulletin has been reviewed and approved by:  
Davinder Sidhu, MD, FRCPC, Section Chief, Transfusion Medicine, South Sector  
Leland Baskin, MD, FCAP, FAACC, Associate Medical Director, South Sector

www.albertaprecisionlabs.ca